InvestorsHub Logo
Followers 466
Posts 26950
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 2164

Wednesday, 08/29/2012 10:18:04 AM

Wednesday, August 29, 2012 10:18:04 AM

Post# of 2237
7:30AM POZEN announces PA32540 provides superior antiplatlet effects over a standard of care regimen in a Phase 1 study (POZN) 6.64 : The data from the Co-Rx Study suggest that PA32540 given in conjunction with clopidogrel, dosed at least 10 hours apart, resulted in greater antiplatelet effects than synchronously administered EC aspirin, clopidogrel, and EC omeprazole, in healthy volunteers. These data were further presented at the European Society of Cardiologists 2012 Congress in Munich, Germany on August 26, 2012. PA32540, an investigational coordinated-delivery tablet of immediate-release omeprazole, a proton pump inhibitor, layered around pH-sensitive aspirin, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.